Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $85,000.

  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) rose 33.33% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $99,000, marking a year-over-year increase of 6.45%. This contributed to the annual value of $85,000 for FY2024, which is 43.71% down from last year.
  • According to the latest figures from FY2024, Corvus Pharmaceuticals' Depreciation & Amortization (CF) is $85,000, which was down 43.71% from $151,000 recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $632,000 in FY2020 and a low of $85,000 during FY2024.
  • For the 3-year period, Corvus Pharmaceuticals' Depreciation & Amortization (CF) averaged around $201,000, with its median value being $151,000 (2023).
  • Data for Corvus Pharmaceuticals' Depreciation & Amortization (CF) shows a maximum YoY plummeted of 58.86% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Depreciation & Amortization (CF) stood at $632,000 in 2020, then declined by 27.22% to $460,000 in 2021, then declined by 20.22% to $367,000 in 2022, then slumped by 58.86% to $151,000 in 2023, then crashed by 43.71% to $85,000 in 2024.